Biopharmx Corp (NYSEAMERICAN:BPMX) dropped 7.1% on Friday . The company traded as low as $0.13 and last traded at $0.13. Approximately 15,808,400 shares were traded during mid-day trading, an increase of 91% from the average daily volume of 8,269,592 shares. The stock had previously closed at $0.14.

Separately, Maxim Group restated a “buy” rating and issued a $1.50 price objective on shares of Biopharmx in a report on Friday, December 8th.

The stock has a market capitalization of $14.93, a price-to-earnings ratio of -0.48 and a beta of 1.33.

Biopharmx (NYSEAMERICAN:BPMX) last issued its quarterly earnings data on Thursday, December 7th. The biotechnology company reported ($0.05) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.05).

In related news, Director Stephen Morlock acquired 330,000 shares of the stock in a transaction that occurred on Friday, November 24th. The shares were bought at an average price of $0.15 per share, for a total transaction of $49,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $0.20, for a total transaction of $59,278.80. The disclosure for this sale can be found here.

ILLEGAL ACTIVITY NOTICE: “Biopharmx (BPMX) Trading Down 7.1%” was reported by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.